MedWatch

Leo Innovation Lab says sale of spinoff is "stamp of approval"

The sale of healthcare app company Omhu to US-based Medable is the first time that Leo Innovation Lab has completely let go of one of its companies. CEO Anne Cathrine Fleischer sees the sale as a stamp of approval.

Anne Cathrine Fleischer, CEO at Leo Innovation Lab | Photo: Mathilde Gilling / Leo Innovation Lab / PR

Just two years after app company Omhu was spun out from Leo Innovation Lab, Leo has chosen to sell all of its shares in the firm to US-based Medable for an undisclosed sum. It is the first time that Leo Innovation Lab has sold the entirety of one of its spinoff companies.

Omhu has developed a dermatological diagnostics app, where patients can take pictures of skin abnormalities with their smartphones and send them to dermatologists.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs